Neurodegenerative disease
Galimedix establishes Alzheimer’s Disease Scientific Advisory Board
The Board will advise Galimedix on scientific and clinical strategy
Pharma-Exclusive Webinar: Redefining Engagement in the AI Era
Join Impetus Digital's pharma-exclusive webinar to discover how compliant AI tools and virtual workflows can elevate static programs into high-retention, interactive experiences without enterprise overhead.
NEW PHARMA-EXCLUSIVE WEBINAR: Beyond the Hype; Practical, Compliant AI Solutions for Pharma Engagement
See how top-tier pharma teams use compliant AI tools and virtual QIPs to capture real-time market intelligence, confidence scores, and audience insights from live dashboards
Alzheimer’s groups call for urgent global focus on women’s brain health
New op-ed published by leaders from the Women’s Alzheimer’s Movement at Cleveland Clinic, Alzheimer’s Research UK and the Alzheimer’s Association
AC Immune amends agreement with Lilly to develop potential Alzheimer’s treatment
The agreement covers the development of new lead tau morphomer candidates
HRW Wins 2026 Artificial Intelligence Excellence Award in the Pharmaceutical Category
Healthcare Research Worldwide (HRW) has been named a winner in the 2026 Artificial Intelligence Excellence Awards in the Pharmaceutical category, recognizing its innovative use of AI to deliver real-world impact....
Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term
The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark
Smarter Learning and Better Outcomes: How AI Can Provide an Advantage in Medical Education
See how AI-powered patient avatars allow physicians to test complex diagnoses and treatment plans in a simulated environment.
Eisai and Biogen’s subcutaneous Leqembi given FDA Priority Review for early Alzheimer’s
Administering the drug subcutaneously rather than intravenously showed similar clinical benefits for patients
Lilly and Indiana University collaborate to expand clinical trial access
The five-year agreement includes a focus on R&D for Alzheimer’s disease
Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease
While the trials did not meet their primary endpoints, they highlighted important biomarker findings